Study of NGR-hTNF in Combination With Cisplatin in Solid Tumor

Solid Tumors Clinical Trial

Official title:

NGR004:A Phase IB Study of NGR-hTNF in Combination With Cisplatin in Patient Affected by Advanced or Metastatic Solid Tumor

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00483093
• Other study ID #: NGR004
• Secondary ID: 2006-006035-42
• Status: Completed
• Phase: Phase 1
• First received: June 5, 2007
• Last updated: May 29, 2014
• Start date: July 2007
• Est. completion date: April 2013

Study information

• Verified date: May 2014
• Source: MolMed S.p.A.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Italy: National Institute of Health
• Study type: Interventional

Clinical Trial Summary

The main objective of the trial is to document the safety of the combination (escalation doses of NGR-hTNF, from 0.2 mcg/sqm to 1.6 mcg/sqm , with a fixed dose of cisplatin, 80 mg/sqm). Safety will be established by clinical and laboratory assessment according to National Cancer Institute Common Toxicity Criteria (NCI-CTC ).

Description:

This is a phase IB, open-label, non-randomized, dose-escalation study that will be conducted in sequential cohorts of patients. Three patients per each cohort are planned.

Patients, with advanced or metastatic solid tumor not amenable of standard therapy will be enrolled.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: April 2013
• Est. primary completion date: June 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients =18 years with advanced or metastatic solid tumor not amenable to any clinical improvement by current standard treatments and suitable for a treatment with cisplatin

• Life expectancy more than 3 months

• ECOG Performance status 0-1

• Absence of any conditions in which hypervolemia and its consequences (e.g. increased stroke volume, elevated blood pressure) may represent a risk for the patient

• Adequate baseline bone marrow, hepatic and renal function, defined as follows:

• Neutrophils > 1.5 x 10^9/L and platelets > 100 x 10^9/L

• Bilirubin < 1.5 x ULN

• AST and/or ALT < 2.5 x ULN in absence of liver metastasis

• AST and/or ALT < 5 x ULN in presence of liver metastasis

• Serum creatinine < 1.5 x ULN

• Creatinine clearance (estimated according to Cockcroft-Gault formula) = 50 ml/min

• Patients may have had prior therapy providing the following conditions are met:

• Chemotherapy, radiation therapy, hormonal therapy or immunotherapy: wash-out period of 28 days

• Corticosteroid therapy wash out period of 14 days

• Surgery: wash-out period of 14 days

• Patients must give written informed consent to participate in the study

Exclusion Criteria:

• Previous signs of severe toxicity platinum related

• Patients must not receive any other investigational agents while on study

• New York Heart Association class III or IV cardiac disease

• Unstable angina

• Patients with myocardial infarction within the last six (6) months

• Patient with significant peripheral vascular disease

• Clinical signs of CNS involvement

• Patients with active or uncontrolled systemic disease/infections or with serious illness or medical conditions, which is incompatible with the protocol

• Known hypersensitivity/allergic reaction to human albumin preparations or to any of the excipients

• Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol

• Pregnancy or lactation. Patients - both males and females - with reproductive potential (i.e. menopausal for less than 1-year and not surgically sterilized) must practice effective contraceptive measures throughout the study. Women of childbearing potential must provide a negative pregnancy test (serum or urine) within 14 days prior to registration

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Solid Tumors

Intervention

Drug:
• NGR-hTNF
iv q3W escalating dose NGR-hTNF up to 1.6 mcg/sqm
• Cisplatin
iv q3W 80 mg/sqm 30 minutes after NGR-hTNF infusion for a maximum of six cycles

Locations

Country	Name	City	State
Italy	Fondazione San Raffaele del Monte Tabor	Milan	Milan,
Italy	Istituto Europeo Oncologico	Milan

Sponsors (1)

Lead Sponsor	Collaborator
MolMed S.p.A.

Country where clinical trial is conducted

Italy, 

References & Publications (1)

Gregorc V, De Braud FG, De Pas TM, Scalamogna R, Citterio G, Milani A, Boselli S, Catania C, Donadoni G, Rossoni G, Ghio D, Spitaleri G, Ammannati C, Colombi S, Caligaris-Cappio F, Lambiase A, Bordignon C. Phase I study of NGR-hTNF, a selective vascular t — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To verify the safety of escalating doses of NGRhTNF (from 0.2 to 1.6 µg/m^2) in combination with cisplatin (80 mg/m^2) every 3 weeks		To recommend a dose regimen of NGR-hTNF + Cisplatin for future phase II trials	Yes
Secondary	To document the preliminary antitumor activity of the combination in terms of objective response rate according to RECIST criteria		every six weeks	No
Secondary	To evaluate the pharmacokinetic profiles of the combination of NGR-hTNF and cisplatin		During the study	No
Secondary	To measure plasma levels of sTNFRs and anti-NGR-hTNF antibodies		During the study	No